Tiloron - instructions for use, dose, side effects, contraindications

Excipients: lactose monohydrate (sugar milk) - 84.40 mg, microcrystalline cellulose - 28.50 mg, croscarmellose sodium - 7.60 mg, povidone-K25 - 7.60 mg, magnesium stearate - 1.90 mg.

Shell composition: hypromellose - 3.42 mg, macrogol-4000 - 0.84 mg, titanium dioxide - 1.68 mg, tropeolin-0-0.06 mg.

Composition per 1 tablet 125 mg:

Active substance: tylorone dihydrochloride (tilorone) - 125.00 mg.

Excipients: lactose monohydrate (milk sugar) - 103,00 mg, microcrystalline cellulose - 45,00 mg, croscarmellose sodium - 12,00 mg, povidone-K25 - 12,00 mg, magnesium stearate - 3,00 mg.

Shell composition: hypromellose - 5.70 mg, macrogol-4000 - 1.40 mg, titanium dioxide - 2.80 mg, tropeolin-0 dye-0.10 mg.

Description:TOrifle, biconvex tablets, covered with a film coat from yellow to orange. On the cross-section of the tablet are visible: the film shell and the core of orange color, white or orange impregnations of different shades are allowed.

Pharmacotherapeutic group:antiviral immunostimulating agent - inducer of the formation of interferons

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

A low-molecular synthetic interferon inducer that stimulates the formation of alpha, beta, gamma and lambda interferons in the body. The main producers of interferon in response to the introduction of Tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours. Tyloron has immunomodulatory and antiviral effect. After a single oral administration of tylorone in a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda was determined after 24 hours, interferon alfa after 48 hours.Induction of interferon lambda in the lung tissue contributes to an increase in antiviral protection of the respiratory tract in influenza and other respiratory viral infections. In human leukocytes induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics:

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins. The drug is practically unchanged through the intestine (70%) and through the kidneys (9%). The half-life is 48 hours. The drug is not biotransformed and does not accumulate in the body.

Indications:

In adults treatment and prevention of influenza, other SARS; treatment of viral hepatitis A, B and C; treatment of herpetic and cytomegalovirus infection; in the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.); in the complex therapy of urogenital and respiratory chlamydia; in the complex therapy of pulmonary tuberculosis.

In children older than 7 years - for treatment of influenza and other acute respiratory infections.

Contraindications:

- Hypersensitivity to tilorone and other components of the drug;

- period of pregnancy and lactation;

- children's age till 7 years;

- hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:AT the composition of complex therapy of infectious-allergic and viral encephalomyelitis drug is used under the supervision of a doctor.

Pregnancy and lactation:

The drug is contraindicated during pregnancy.

If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

Dosing and Administration:

Tyloron is taken orally after eating.

Adults

For the treatment of viral hepatitis A - on the first day of 125 mg 2 times, then 125 mg after 48 hours. For the course - 1.25 g.

For the treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, the course of treatment - 2 g. With protracted hepatitis B, 125 mg twice a day on the first day, then 125 mg after 48 hours. The course of treatment - 2.5 g.

With chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g to 2.5 g), 125 mg per week. The course dose of tyloron from 3.75 g to 5 g, the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C - 125 mg daily for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g.

With chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (2.5 g) of 125 mg per week. The course dose of tyloron - 5 g, the duration of therapy - 6 months, depending on the results of biochemical, immunological, morphological markers of activity of the process.

With the complex treatment of infectious-allergic and viral encephalomyelitis - 125-250 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

To treat influenza and other ARVI - 125 mg daily for the first 2 days of treatment, then 125 mg after 48 hours. The course is 750 mg.

For the prevention of influenza and other ARVI - 125 mg once a week for 6 weeks.

The course is 750 mg.

For the treatment of herpetic, cytomegalovirus infection - the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 - 2.5 g.

With urogenital and respiratory chlamydiosis - the first two days of 125 mg, then 48 hours after 125 mg. Course dose -1.25 g.

With the comprehensive therapy of pulmonary tuberculosis - 250 mg first two days of treatment, then 125 mg after 48 hours. The course dose is 2.5 g.

Children older than 7 years

In children older than 7 years with uncomplicated forms of influenza and other ARVI - 60 mg once a day on the 1 st, 2 nd and 4 th days from the beginning of treatment. The course dose is 180 mg.

When complications of influenza or other ARVI occur - 60 mg once a day on the 1 st, 2 nd, 4 th and 6 th day from the beginning of treatment. The course dose is 0.24 g.

Side effects:Allergic reactions, dyspeptic phenomena, short-term chills are possible.

Overdose:

Cases of drug overdose are not known.

Interaction:

Compatible with antibiotics and drugs traditional treatment of viral and bacterial diseases.

Clinically significant interaction of tylorone with antibiotics and traditional treatment of viral and bacterial diseases was not revealed.

Effect on the ability to drive transp. cf. and fur:

The drug does not adversely affect the ability to drive vehicles and engage in other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Tablets, film-coated, 60 mg, 125 mg.

Packaging:

By 6, 7, 10, 14, 20, 25 or 30 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

10, 20, 30, 40, 50, 100 or 500 tablets in cans of polyethylene terephthalate for medicinal products sealed with caps screwed with a first opening control or a "push-turn" system of polypropylene or polyethylene, or polypropylene cans for drugs sealed lids pulled with the control of the first opening of polyethylene,or polypropylene cans for medicinal products sealed with caps tightened with the control of the first opening of high pressure polyethylene.

One jar or 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-003548

Date of registration:01.04.2016

Date of cancellation:2021-04-01

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZON PHARM, LLC Russia

Information update date: & nbsp13.06.2016

Illustrated instructions

Instructions

Tyloron (Tilorone)